129 related articles for article (PubMed ID: 16937357)
61. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
62. [Methylation status of RASSF1A gene promoter in upper tract urothelial carcinoma and its clinical significance].
Liu J; Xiong GY; Tang Q; Fang D; Li XS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):571-578. PubMed ID: 29263491
[TBL] [Abstract][Full Text] [Related]
63. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia.
Wong IH; Chan J; Wong J; Tam PK
Clin Cancer Res; 2004 Feb; 10(3):994-1002. PubMed ID: 14871978
[TBL] [Abstract][Full Text] [Related]
64. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.
Danielsen SA; Lind GE; Kolberg M; Høland M; Bjerkehagen B; Sundby Hall K; van den Berg E; Mertens F; Smeland S; Picci P; Lothe RA
Neuro Oncol; 2015 Jan; 17(1):63-9. PubMed ID: 25038505
[TBL] [Abstract][Full Text] [Related]
65. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas.
Götze S; Wolter M; Reifenberger G; Müller O; Sievers S
Int J Cancer; 2010 Jun; 126(11):2584-93. PubMed ID: 19847810
[TBL] [Abstract][Full Text] [Related]
66. Overexpression of
Beck A; Trippel F; Wagner A; Joppien S; Felle M; Vokuhl C; Schwarzmayr T; Strom TM; von Schweinitz D; Längst G; Kappler R
Clin Epigenetics; 2018; 10():27. PubMed ID: 29507645
[TBL] [Abstract][Full Text] [Related]
67. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
68. β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.
Schirosi L; Mazzotta A; Opinto G; Pinto R; Graziano G; Tommasi S; Fucci L; Simone G; Mangia A
Oncotarget; 2016 Oct; 7(42):67841-67850. PubMed ID: 27765918
[TBL] [Abstract][Full Text] [Related]
69. Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer.
Vu TL; Nguyen TT; Doan VTH; Vo LTT
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1887-1893. PubMed ID: 30049201
[TBL] [Abstract][Full Text] [Related]
70. [Different hypermethylation status of RASSF1A in medulloblastoma and supratentorial primitive neuroectodermal tumor].
Chang Q; Ng HK
Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):24-8. PubMed ID: 17374234
[TBL] [Abstract][Full Text] [Related]
71. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
Dulaimi E; Uzzo RG; Greenberg RE; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Mar; 10(6):1887-93. PubMed ID: 15041703
[TBL] [Abstract][Full Text] [Related]
72. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
73. [Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer].
Zhang H; Zhang S; Zhang Z; Jia H; Gu S; Zhao D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):311-6. PubMed ID: 20677556
[TBL] [Abstract][Full Text] [Related]
74. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
[TBL] [Abstract][Full Text] [Related]
75. Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China.
Zhou SL; Cui J; Fan ZM; Li XM; Li JL; Liu BC; Zhang DY; Liu HY; Zhao XK; Song X; Wang R; Yan ZC; Yi HX; Wang LD
BMC Cancer; 2013 May; 13():259. PubMed ID: 23705663
[TBL] [Abstract][Full Text] [Related]
76. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
[TBL] [Abstract][Full Text] [Related]
77. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
78. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
79. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
80. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
